145 related articles for article (PubMed ID: 28000414)
1. Identification of CLK1 Inhibitors by a Fragment-linking Based Virtual Screening.
Walter A; Chaikuad A; Loaëc N; Preu L; Knapp S; Meijer L; Kunick C; Koch O
Mol Inform; 2017 Apr; 36(4):. PubMed ID: 28000414
[TBL] [Abstract][Full Text] [Related]
2. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.
Jain P; Karthikeyan C; Moorthy NS; Waiker DK; Jain AK; Trivedi P
Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585
[TBL] [Abstract][Full Text] [Related]
3. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
[TBL] [Abstract][Full Text] [Related]
4. 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.
Falke H; Chaikuad A; Becker A; Loaëc N; Lozach O; Abu Jhaisha S; Becker W; Jones PG; Preu L; Baumann K; Knapp S; Meijer L; Kunick C
J Med Chem; 2015 Apr; 58(7):3131-43. PubMed ID: 25730262
[TBL] [Abstract][Full Text] [Related]
5. A conserved sequence motif bridges two protein kinases for enhanced phosphorylation and nuclear function of a splicing factor.
Aubol BE; Fattet L; Adams JA
FEBS J; 2021 Jan; 288(2):566-581. PubMed ID: 32359191
[TBL] [Abstract][Full Text] [Related]
6. Drug Discovery of Host CLK1 Inhibitors for Influenza Treatment.
Zu M; Li C; Fang JS; Lian WW; Liu AL; Zheng LS; Du GH
Molecules; 2015 Nov; 20(11):19735-47. PubMed ID: 26540031
[TBL] [Abstract][Full Text] [Related]
7. Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation.
Bullock AN; Das S; Debreczeni JE; Rellos P; Fedorov O; Niesen FH; Guo K; Papagrigoriou E; Amos AL; Cho S; Turk BE; Ghosh G; Knapp S
Structure; 2009 Mar; 17(3):352-62. PubMed ID: 19278650
[TBL] [Abstract][Full Text] [Related]
8. In silico identification of putative bifunctional Plk1 inhibitors by integrative virtual screening and structural dynamics approach.
Shafique S; Bibi N; Rashid S
J Theor Biol; 2016 Jan; 388():72-84. PubMed ID: 26493360
[TBL] [Abstract][Full Text] [Related]
9. Nuclear protein kinase CLK1 uses a non-traditional docking mechanism to select physiological substrates.
Keshwani MM; Hailey KL; Aubol BE; Fattet L; McGlone ML; Jennings PA; Adams JA
Biochem J; 2015 Dec; 472(3):329-38. PubMed ID: 26443864
[TBL] [Abstract][Full Text] [Related]
10. Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands.
Murár M; Dobiaš J; Šramel P; Addová G; Hanquet G; Boháč A
Eur J Med Chem; 2017 Jan; 126():754-761. PubMed ID: 27940419
[TBL] [Abstract][Full Text] [Related]
11. Benzobisthiazoles Represent a Novel Scaffold for Kinase Inhibitors of CLK Family Members.
Prak K; Kriston-Vizi J; Chan AW; Luft C; Costa JR; Pengo N; Ketteler R
Biochemistry; 2016 Jan; 55(3):608-17. PubMed ID: 26701387
[TBL] [Abstract][Full Text] [Related]
12. Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype.
Walter A; Chaikuad A; Helmer R; Loaëc N; Preu L; Ott I; Knapp S; Meijer L; Kunick C
PLoS One; 2018; 13(5):e0196761. PubMed ID: 29723265
[TBL] [Abstract][Full Text] [Related]
13. Regulation of influenza A virus mRNA splicing by CLK1.
Artarini A; Meyer M; Shin YJ; Huber K; Hilz N; Bracher F; Eros D; Orfi L; Keri G; Goedert S; Neuenschwander M; von Kries J; Domovich-Eisenberg Y; Dekel N; Szabadkai I; Lebendiker M; Horváth Z; Danieli T; Livnah O; Moncorgé O; Frise R; Barclay W; Meyer TF; Karlas A
Antiviral Res; 2019 Aug; 168():187-196. PubMed ID: 31176694
[TBL] [Abstract][Full Text] [Related]
14. Disordered protein interactions for an ordered cellular transition: Cdc2-like kinase 1 is transported to the nucleus via its Ser-Arg protein substrate.
George A; Aubol BE; Fattet L; Adams JA
J Biol Chem; 2019 Jun; 294(24):9631-9641. PubMed ID: 31064840
[TBL] [Abstract][Full Text] [Related]
15. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing.
Fedorov O; Huber K; Eisenreich A; Filippakopoulos P; King O; Bullock AN; Szklarczyk D; Jensen LJ; Fabbro D; Trappe J; Rauch U; Bracher F; Knapp S
Chem Biol; 2011 Jan; 18(1):67-76. PubMed ID: 21276940
[TBL] [Abstract][Full Text] [Related]
16. Multi-step virtual screening to develop selective DYRK1A inhibitors.
Koyama T; Yamaotsu N; Nakagome I; Ozawa SI; Yoshida T; Hayakawa D; Hirono S
J Mol Graph Model; 2017 Mar; 72():229-239. PubMed ID: 28129593
[TBL] [Abstract][Full Text] [Related]
17. Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.
Shahroz MM; Sharma HK; Altamimi ASA; Alamri MA; Ali A; Ali A; Alqahtani S; Altharawi A; Alabbas AB; Alossaimi MA; Riadi Y; Firoz A; Afzal O
Molecules; 2022 Feb; 27(4):. PubMed ID: 35208955
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors.
Schmitt C; Kail D; Mariano M; Empting M; Weber N; Paul T; Hartmann RW; Engel M
PLoS One; 2014; 9(3):e87851. PubMed ID: 24676346
[TBL] [Abstract][Full Text] [Related]
19. Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945.
Lee JY; Yun JS; Kim WK; Chun HS; Jin H; Cho S; Chang JH
Biomed Res Int; 2019; 2019():6125068. PubMed ID: 31531359
[TBL] [Abstract][Full Text] [Related]
20. 5-Methoxybenzothiophene-2-Carboxamides as Inhibitors of Clk1/4: Optimization of Selectivity and Cellular Potency.
ElHady AK; El-Gamil DS; Chen PJ; Hwang TL; Abadi AH; Abdel-Halim M; Engel M
Molecules; 2021 Feb; 26(4):. PubMed ID: 33668683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
